

Quizartinib

Catalog No: tcsc0211



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg

Size: 200mg

Size: 500mg

Size: 1g

Size: 2g

Size: 5g



Specifications

CAS No:

950769-58-1

Formula:

$C_{29}H_{32}N_6O_4S$

Pathway:

Protein Tyrosine Kinase/RTK;Autophagy

Target:

FLT3;Autophagy

Purity / Grade:

>98%

Solubility:DMSO : ≥ 33 mg/mL (58.86 mM)**Alternative Names:**

AC220

Observed Molecular Weight:

560.67


Product Description

Quizartinib is a uniquely potent and selective **Flt3** inhibitor with K_d (FLT3 binding affinity) of 1.6 ± 0.7 nM in Biochemical assay.

IC50 & Target: K_d : 1.6 ± 0.7 nM (Flt3)^[1]

In Vitro: Quizartinib (AC220) is a novel compound expressly optimized as a FLT3 inhibitor for the treatment of acute myeloid leukemia (AML). Quizartinib inhibits FLT3-WT and FLT3-ITD autophosphorylation with IC_{50} of 4.2 ± 0.3 nM and 1.1 ± 0.1 nM, respectively. Quizartinib inhibits MV4-11 and A375 cells with IC_{50} of 0.56 ± 0.3 nM and $>10\ 000$ nM, respectively. Quizartinib inhibits FLT3 with low nanomolar potency in cellular assays and is highly selective when screened against the majority of the human protein kinome^[1].

In Vivo: Quizartinib (AC220) inhibits FLT3 activity in vivo, significantly extends survival in a mouse model of FLT3-ITD AML at doses as low as 1 mg/kg when dosed orally once a day, eradicates tumors in a FLT3-dependent mouse xenograft model at 10 mg/kg, and potently inhibits FLT3 activity in primary patient cells. The oral bioavailability of Quizartinib, determined in rats by comparing oral and intravenous pharmacokinetics at 3 mg/kg, is approximately 40%. A single 10 mg/kg dose of Quizartinib is administered by oral gavage, and mice are killed at 2 time points after dosing, using groups of 4 animals each. Quantitation of total FLT3 and phospho-FLT3 in tumor samples revealed time-dependent inhibition of FLT3 autophosphorylation. FLT3 activity is inhibited by 90% at 2 hours, and 40% at 24 hours after administration. The extent of inhibition therefore correlated well with the expected free Quizartinib plasma levels, based on pharmacokinetic experiments^[1].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!